                         SEQUENCE LISTING

<110>  BICYCLETX LIMITED
 
<120>  HETEROTANDEM BICYCLIC PEPTIDE COMPLEX

<130>  BIC-C-P2832PCT

<150>  62/880,191
<151>  2019-07-30

<150>  62/910,088
<151>  2019-10-03

<150>  62/931,442
<151>  2019-11-06

<150>  63/022,667
<151>  2020-05-11

<150>  63/024,715
<151>  2020-05-14

<160>  4     

<170>  PatentIn version 3.5

<210>  1
<211>  15
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic Peptide


<220>
<221>  Xaa
<222>  (3)..(3)
<223>  Xaa is 1Nal

<220>
<221>  Xaa
<222>  (7)..(7)
<223>  Xaa is HArg

<220>
<221>  Xaa
<222>  (13)..(13)
<223>  Xaa is HyP

<400>  1

Cys Pro Xaa Asp Cys Met Xaa Asp Trp Ser Thr Pro Xaa Trp Cys 
1               5                   10                  15  


<210>  2
<211>  16
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic Peptide


<220>
<221>  Xaa
<222>  (2)..(2)
<223>  Xaa is tBuAla

<220>
<221>  Xaa
<222>  (5)..(5)
<223>  Xaa is D-Lys(PYA)

<220>
<221>  Xaa
<222>  (14)..(14)
<223>  Xaa is Nle

<400>  2

Cys Xaa Pro Glu Xaa Pro Tyr Cys Phe Ala Asp Pro Tyr Xaa Cys Ala 
1               5                   10                  15      


<210>  3
<211>  16
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic Peptide


<220>
<221>  Xaa
<222>  (2)..(2)
<223>  Xaa is tBuAla

<220>
<221>  Xaa
<222>  (5)..(5)
<223>  Xaa is D-Lys(PYA)

<220>
<221>  Xaa
<222>  (14)..(14)
<223>  Xaa is Nle

<400>  3

Cys Xaa Pro Glu Xaa Pro Tyr Cys Phe Ala Asp Pro Tyr Xaa Cys Ala 
1               5                   10                  15      


<210>  4
<211>  16
<212>  PRT
<213>  Artificial

<220>
<223>  Synthetic Peptide


<220>
<221>  Xaa
<222>  (2)..(2)
<223>  Xaa is tBuAla

<220>
<221>  Xaa
<222>  (5)..(5)
<223>  Xaa is D-Lys(PYA)

<220>
<221>  Xaa
<222>  (14)..(14)
<223>  Xaa is Nle

<400>  4

Cys Xaa Pro Glu Xaa Pro Tyr Cys Phe Ala Asp Pro Tyr Xaa Cys Lys 
1               5                   10                  15      


